iScience (Nov 2023)

The transcription factor IRF4 determines the anti-tumor immunity of CD8+ T cells

  • Hui Yan,
  • Yulin Dai,
  • Xiaolong Zhang,
  • Hedong Zhang,
  • Xiang Xiao,
  • Jinfei Fu,
  • Dawei Zou,
  • Anze Yu,
  • Tao Jiang,
  • Xian C. Li,
  • Zhongming Zhao,
  • Wenhao Chen

Journal volume & issue
Vol. 26, no. 11
p. 108087

Abstract

Read online

Summary: Understanding the factors that regulate T cell infiltration and functional states in solid tumors is crucial for advancing cancer immunotherapies. Here, we discovered that the expression of interferon regulatory factor 4 (IRF4) was a critical T cell intrinsic requirement for effective anti-tumor immunity. Mice with T-cell-specific ablation of IRF4 showed significantly reduced T cell tumor infiltration and function, resulting in accelerated growth of subcutaneous syngeneic tumors and allowing the growth of allogeneic tumors. Additionally, engineered overexpression of IRF4 in anti-tumor CD8+ T cells that were adoptively transferred significantly promoted their tumor infiltration and transition from a naive/memory-like cell state into effector T cell states. As a result, IRF4-engineered anti-tumor T cells exhibited significantly improved anti-tumor efficacy, and inhibited tumor growth either alone or in combination with PD-L1 blockade. These findings identify IRF4 as a crucial cell-intrinsic driver of T cell infiltration and function in tumors, emphasizing the potential of IRF4-engineering as an immunotherapeutic approach.

Keywords